Key facts
- It has raised $490.5M across 3 recorded rounds; the latest was Later Stage VC (Series C) ($165.0M) in May 2021.
- Notable investors include General Catalyst, D1 Capital Partners, Tiger Global Management, 8VC, OrbiMed — 26 tracked in total.
- PathAI has filed 2 Form Ds with the SEC since 2017, most recently Apr 2019 ($60.0M sold to 15 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 26 names
- ·Watchlist + deal alerts for PathAI
Funding rounds
3 roundsAbout PathAI
Developer of an artificial intelligence-powered research platform intended to improve the accuracy and efficiency of cancer diagnosis and treatment. The company's platform applies machine and deep learning techniques to aggregated sets in order to detect cancerous cells separately, enabling pathologists to diagnose cancer patients rapidly and accurately.
- Industry
- Discovery Tools (Healthcare)
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2016
- Employees
- 268
- Website
- pathai.com/
- Ownership
- Privately Held (backing)
PathAI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PathAI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PathAI in its N-PORT filings yet. We sweep new filings monthly.